Cellectis
CLLS
#7231
Rank
HK$3.73 B
Marketcap
HK$35.94
Share price
-2.53%
Change (1 day)
135.70%
Change (1 year)

Revenue for Cellectis (CLLS)

Revenue in 2025 (TTM): HK$0.58 Billion

According to Cellectis's latest financial reports the company's current revenue (TTM ) is HK$0.58 Billion. In 2024 the company made a revenue of HK$0.32 Billion an increase over the revenue in the year 2023 that were of HK$5.89 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Cellectis from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) HK$0.58 B82.05%
2024 HK$0.32 B5364.72%
2023 HK$5.89 M-96.04%
2022 HK$0.14 B-66.67%
2021 HK$0.44 B-21.19%
2020 HK$0.56 B381.69%
2019 HK$0.11 B16.83%
2018 HK$0.10 B-48.68%
2017 HK$0.19 B-40.38%
2016 HK$0.32 B-22.29%
2015 HK$0.42 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
uniQure
QURE
HK$0.12 B-79.07%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
HK$7.96 B 1,260.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
HK$110.83 B 18,829.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
HK$0.78 B 33.39%๐Ÿ‡บ๐Ÿ‡ธ USA